Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients.

Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients.

Detalles Bibliográficos
Autores principales:	Generali, D, Fox, S, Buffa, F, Berruti, A, Brizzi, M, Allevi, G, Bonardi, S, Dogliotti, L, Bottini, A, Harris, A
Formato:	Conference item
Publicado:	2006

Ejemplares similares

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
por: Generali, D, et al.
Publicado: (2006)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
por: Generali, D, et al.
Publicado: (2006)

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
por: Generali, D, et al.
Publicado: (2009)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
por: Mele, T, et al.
Publicado: (2010)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
por: Mele, T, et al.
Publicado: (2010)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
por: Fox, S, et al.
Publicado: (2011)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
por: Fox, S, et al.
Publicado: (2011)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer
por: Generali, D, et al.
Publicado: (2007)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.
por: Generali, D, et al.
Publicado: (2007)

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
por: Generali, D, et al.
Publicado: (2009)

Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
por: Fox, S, et al.
Publicado: (2006)

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
por: Generali, D, et al.
Publicado: (2008)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
por: Generali, D, et al.
Publicado: (2008)

DOWN-REGULATION OF HYPOXIA INDUCIBILE FACTOR-1 alpha (HIF-1 alpha) EXPRESSION, THROUGH mTOR PATHWAY, BY LETROZOLE (FEMARA (R)) IN ER plus ve BREAST CANCER PATIENTS: CLINICAL IMPLICATIONS
por: Foroni, C, et al.
Publicado: (2009)

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
por: Generali, D, et al.
Publicado: (2011)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
por: Allevi, G, et al.
Publicado: (2013)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
por: Allevi, G, et al.
Publicado: (2013)

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer
por: Andreis, D, et al.
Publicado: (2016)

Neoadjuvant Chemo-Endocrine Therapy for Hormone Receptor Positive Breast Cancer: A Meta-Analysis
por: Zhen-Yu Li, et al.
Publicado: (2023-04-01)

Editorial: Endocrine Frailty in the Elderly
por: Antonio Aversa, et al.
Publicado: (2019-09-01)

To Chemo or Not to Chemo… That Is the Question
por: Maria Felisa Eva B. Martin, et al.
Publicado: (2023-08-01)

The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
por: Milani, M, et al.
Publicado: (2009)

Endocrine markers in critical illness
por: Vaman Khadilkar, et al.
Publicado: (2017-01-01)

Early post-surgical recurrence of metastatic vertebral neuro-endocrine tumour treated effectively with chemo-radiotherapy
por: Kaliya-Perumal Arun-Kumar, et al.
Publicado: (2019-03-01)

Early breast cancer in elderly women: surgery or primary endocrine therapy?
por: Accurso A, et al.
Publicado: (2010-05-01)

Molecular markers in the CHART trial
por: Wilson, G, et al.
Publicado: (2005)

The Value of Serum Biomarkers (Bc1, Bc2, Bc3) in the Diagnosis of Early Breast Cancer
por: Kemal Atahan, Hakan Küpeli, Serhat Gür, Türkan Yiğitbaşı, Yasemin Baskın, Seyran Yiğit, Mehmet Deniz, Atilla Çökmez, Ercüment Tarcan
Publicado: (2011-01-01)

Angiogenesis in endocrine tumors.
por: Turner, H, et al.
Publicado: (2003)

Observation of the decay Bc±→J/ψπ± and measurement of the Bc± mass
por: Aaltonen, T, et al.
Publicado: (2008)

S100β as a serum marker in endocrine resistant breast cancer
por: Sara Charmsaz, et al.
Publicado: (2017-04-01)

Survival in elderly follicular lymphoma patients who receive frontline chemo-immunotherapy.
por: Griffiths, R, et al.
Publicado: (2010)

Dendritic Architecture of Principal Basolateral Amygdala Neurons Changes Congruently with Endocrine Response to Stress
por: Yee, Poh Soh, et al.
Publicado: (2018)

Observation of the decay Bc+/--->J/psipi+/- and measurement of the Bc+/- mass.
por: Aaltonen, T, et al.
Publicado: (2008)

Němčice and Pistiros: Glass Beads as Historical Markers in the Third Century BC
por: Natalie Venclová
Publicado: (2015-12-01)

Singularities of Polishing Substrates GaAs by Chemo-Dynamical and Non-Contact Chemo-Mechanical Methods
por: G. A. Pashchenko, et al.
Publicado: (2016-10-01)

Spectroscopy of $$\mathbf {B_c}$$ Bc mesons and the possibility of finding exotic $$\mathbf {B_c}$$ Bc -like structures
por: Pablo G. Ortega, et al.
Publicado: (2020-03-01)

Observation of the Bc meson in the exclusive decay Bc→J/ψπ
por: Abazov, V, et al.
Publicado: (2008)

['Conference BC 2021', 'Conference BC 2021']
por: Josep Torn
Publicado: (2022-01-01)

Inflammatory Marker Predicts Outcome of Oral Squamous Cell Carcinoma Receiving Chemo-Radiotherapy
por: Sun W, et al.
Publicado: (2020-12-01)

Evidence for the exclusive decay Bc±→J/ψπ± and measurement of the mass of the Bc± meson
por: Abulencia, A, et al.
Publicado: (2006)